Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trontinemab versus placebo in early symptomatic Alzheimer's disease
NL-OMON59361Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo (2 arms). Primary endpoint: Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes. Started Jan 2026; status: active, not recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON59361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59361.